File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Ticagrelor reduced risk of infection compared with clopidogrel: a meta-analysis
Title | Ticagrelor reduced risk of infection compared with clopidogrel: a meta-analysis |
---|---|
Authors | |
Issue Date | 2020 |
Publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/ |
Citation | The 25th Annual Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 34, abstract no. 56 How to Cite? |
Abstract | Introduction: Ticagrelor has antibacterial activity in vitro.1 In the PLATO (Platelet Inhibition and Patient
Outcomes) trial, ticagrelor reduced the incidence of pneumonia and improved lung function. We conducted a meta-analysis to investigate if ticagrelor reduces the risk of infections.
Methods: We searched Medline, Embase, Cochrane Library, and clinicaltrials.gov for randomised controlled trials comparing ticagrelor and clopidogrel that have reported the incidence of infection. The primary outcome was pneumonia. Secondary outcomes were upper respiratory tract infection (URTI), urinary tract infection (UTI), and sepsis. Odds ratios (ORs) and 95% confidence intervals (CIs) were combined with random-effects model in RevMan version 5.3.
Results: Out of 5231 citations, 13 trials with altogether 90 679 patients were included. Ticagrelor was associated with a lower risk of pneumonia (OR=0.79, 95% CI=0.66-0.95) compared with clopidogrel, but no statistically significant difference was observed for URTI (OR=0.68, 95% CI=0.33-1.43), UTI (OR=1.06, 95% CI=0.75-1.49), or sepsis (OR=0.79, 95% CI=0.52-1.21).
Conclusion: Our meta-analysis provides further evidence that ticagrelor reduces the risk of pneumonia, when compared with clopidogrel. Our results did not show a reduction in URTI, UTI, or sepsis. Further research is needed to investigate the effect of ticagrelor on infections.
Reference: 1. Lancellotti P, Musumeci L, Jacques N, et al. Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant Gram-positive bacteria. JAMA Cardiol 2019;4:596-9. |
Persistent Identifier | http://hdl.handle.net/10722/281733 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 0.261 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, HL | - |
dc.contributor.author | Tsoi, MF | - |
dc.contributor.author | Feng, Q | - |
dc.contributor.author | Fei, T | - |
dc.contributor.author | Cheung, BMY | - |
dc.date.accessioned | 2020-03-22T04:18:53Z | - |
dc.date.available | 2020-03-22T04:18:53Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | The 25th Annual Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 34, abstract no. 56 | - |
dc.identifier.issn | 1024-2708 | - |
dc.identifier.uri | http://hdl.handle.net/10722/281733 | - |
dc.description.abstract | Introduction: Ticagrelor has antibacterial activity in vitro.1 In the PLATO (Platelet Inhibition and Patient Outcomes) trial, ticagrelor reduced the incidence of pneumonia and improved lung function. We conducted a meta-analysis to investigate if ticagrelor reduces the risk of infections. Methods: We searched Medline, Embase, Cochrane Library, and clinicaltrials.gov for randomised controlled trials comparing ticagrelor and clopidogrel that have reported the incidence of infection. The primary outcome was pneumonia. Secondary outcomes were upper respiratory tract infection (URTI), urinary tract infection (UTI), and sepsis. Odds ratios (ORs) and 95% confidence intervals (CIs) were combined with random-effects model in RevMan version 5.3. Results: Out of 5231 citations, 13 trials with altogether 90 679 patients were included. Ticagrelor was associated with a lower risk of pneumonia (OR=0.79, 95% CI=0.66-0.95) compared with clopidogrel, but no statistically significant difference was observed for URTI (OR=0.68, 95% CI=0.33-1.43), UTI (OR=1.06, 95% CI=0.75-1.49), or sepsis (OR=0.79, 95% CI=0.52-1.21). Conclusion: Our meta-analysis provides further evidence that ticagrelor reduces the risk of pneumonia, when compared with clopidogrel. Our results did not show a reduction in URTI, UTI, or sepsis. Further research is needed to investigate the effect of ticagrelor on infections. Reference: 1. Lancellotti P, Musumeci L, Jacques N, et al. Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant Gram-positive bacteria. JAMA Cardiol 2019;4:596-9. | - |
dc.language | eng | - |
dc.publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/ | - |
dc.relation.ispartof | Hong Kong Medical Journal | - |
dc.relation.ispartof | 25th Medical Research Conference | - |
dc.rights | Hong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press. | - |
dc.title | Ticagrelor reduced risk of infection compared with clopidogrel: a meta-analysis | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Tsoi, MF: smftsoi@hku.hk | - |
dc.identifier.email | Feng, Q: qifeng@hku.hk | - |
dc.identifier.email | Cheung, BMY: mycheung@hkucc.hku.hk | - |
dc.identifier.authority | Cheung, BMY=rp01321 | - |
dc.identifier.hkuros | 309421 | - |
dc.identifier.volume | 26 | - |
dc.identifier.issue | 1, Suppl. 1 | - |
dc.identifier.spage | 34, abstract no. 56 | - |
dc.identifier.epage | 34, abstract no. 56 | - |
dc.publisher.place | Hong Kong | - |
dc.identifier.issnl | 1024-2708 | - |